EVIO Canada’s Keystone Labs Ready for Federal Regulatory Cannabis Pesticide Contamination Testing

Business Wire - finance.yahoo.com Posted 5 years ago


Test results must be provided to LPs before the products can be sold

EVIO Inc. (“EVIO” or the “Company”), (EVIO), the leading North American provider of cannabis testing and scientific research for the regulated cannabis industry, is excited to announce that EVIO Canada’s Keystone Labs is now accepting legal cannabis in the form of dry flower and oil extracts for mandatory pesticide testing.

Health Canada has released mandatory pesticide requirements to all standard cultivators and processors of cannabis. As of today, January 2, 2019, producers are required to submit product samples to independent third-party accredited laboratories for testing cannabis, where they are screened for the absence of 96 specific pesticide ingredients before it can be sold.

“Using state of the art Agilent technology, Keystone is ready to perform Health Canada’s required pesticide testing and deliver accurate data to producers,” said Keystone’s President and founder Jodi McDonald. Adding that, Keystone’s business advantages include competitive pricing, efficient deliverable times, and industry expertise that will surpass market demand.

EVIO Canada acquired 50% stake in Keystone Labs in May 2018.

About Keystone Labs

Keystone Labs Inc., located in Edmonton, Alberta, is a privately held Heath Canada accredited testing facility with a GMP establishment license. Keystone offers a full array of analytical and microbiological testing services for pharmaceutical, biotechnology, medical device, nutraceutical, medical cannabis and related industries.

For more information, visit https://keystonelabs.ca/.

About EVIO Inc.

EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company’s EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply. The Company’s EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system.

For more information, visit www.eviolabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005106/en/